EGFR and non-small cell lung carcinoma: However, in patients with EGFR-mutated non-small cell lung cancer (NSCLC), the combination of AUY922 (70 mg/m2 once weekly) and erlotinib showed modest efficacy (PR 16%), but the clinical benefit was limited due to an increase in adverse effects, such as night blindness [102].